Hyperhomocysteinemia is frequently observed in patients with chronic renal failure and represents an independent cardiovascular risk factor in these patients [1] [2] [3] [4] [5] . Recently, a common C to T mutation at nucleotide position 677 of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene was identified, which may cause elevated total homocysteine plasma levels on the basis of a decreased MTHFR activity and result in lower folate levels in (T/T) homozygous subjects [6 -9] . In chronic hemodialysis patients the allelic frequency of 0.35 of the T allele has been shown to be in line with the frequency of 0.34 in individuals without renal failure [10] . The mean total homocysteine plasma level in hemodialysis patients homozygous for the (T/T) allele was 36.4 mol/ liter, which was 43% higher compared to total homocysteine concentrations of 25.4 mol/liter in patients without mutation and was 3.8 times higher than the mean value of 9.6 mol/liter in healthy non-carriers [10] . Thus far, the mechanisms underlying hyperhomocysteinemia in peritoneal dialysis patients have only been investigated either in small patient populations [3, [11] [12] [13] [14] [15] or in patient populations differing in dialysis procedure or ethnic origin [2, 4, 16] .
We studied the influence of the (C677T) polymorphism in the MTHFR gene on total homocysteine levels as well as plasma folate concentrations in 154 patients maintained on peritoneal dialysis treatment at five peritoneal dialysis units in Austria. Additionally, we analyzed the impact of residual renal function, Kt/V, weekly creatinine clearance, age, gender, folate levels, vitamin B 12 concentrations, creatinine levels, serum albumin concentrations, dialysis center, duration of dialysis, mode of peritoneal dialysis and vitamin intake on total homocysteine levels. Cardiovascular morbidity related to total homocysteine plasma levels was assessed using an arbitrary atherosclerosis score.
METHODS

Study population
One hundred fifty-four patients with end-stage renal failure treated at five peritoneal dialysis units in Austria were investigated. The age of these patients (69 females, 85 males) was 54.0 Ϯ 15.1 years (mean Ϯ SD). Dialysis treatment was initiated because of end-stage renal disease due to diabetic nephropathy (N ϭ 47), shrunken kidneys of unknown etiology (N ϭ 36), chronic glomerulonephritis (N ϭ 27), chronic interstitial nephritis (N ϭ 16), polycystic kidney disease (N ϭ 10), nephrosclerosis (N ϭ 10) and miscellaneous nephropathies in 8 cases. In 20 of the 154 patients peritoneal dialysis was initiated because of secondary kidney graft failure. Twenty-seven patients previously treated with hemodialysis had been switched to peritoneal dialysis. The mean duration of peritoneal dialysis treatment was 1.46 Ϯ 1.27 years. One hundred twenty-one patients were maintained on continuous ambulatory peritoneal dialysis (CAPD) and 33 were treated with automated peritoneal dialysis (APD), including 22 patients on continuous cyclic peritoneal dialysis (CCPD) and 11 patients on intermittent peritoneal dialysis (IPD). Twenty-six of the patients received low dose oral vitamin supplementation therapy routinely (consisting of low dose folate and/or low dose vitamin B 12 and/or low dose vitamin B 6 ). To calculate weekly Kt/V and creatinine clearance, each patient was instructed to collect 24-hour dialysate and urine and to bring a 10 ml sample for laboratory analyses. The average of renal urea clearance and renal creatinine clearance was used to calculate residual renal clearance. The total weekly residual renal and dialysate creatinine clearance was related to 1.73 m 2 of body surface area. All clearance measurements were performed using blood, dialysate and urine samples obtained at the same time-point.
The prevalence of cardiovascular complications was assessed according to Robinson and colleagues [3] . Coronary artery disease and cerebral artery disease was diagnosed if a stenosis of Ͼ 50% was envisaged by angiography or duplex-sonography. Two arbitrary vascular disease scores (VDS 1 and VDS 2) were calculated, based on whether or not the patient suffered from arterial occlusive disease in the coronary, cerebral or peripheral vascular system (VDS 1; 1 point for each affected vascular system; possible score, range 0 to 3). The second score (VDS 2) was applied on the basis of the first score including one additional point for infarction/gangrene or vascular surgery or angioplasty in the different vascular systems (possible score, range 0 to 6). The patient characteristics are summarized in Table 1 .
Age-and sex-matched healthy subjects (N ϭ 154) with normal kidney function and without clinical evidence of cardiovascular disease were selected from 298 healthy volunteers in whom MTHFR-alleles, total homocysteine, folate and vitamin B 12 levels were available.
Written informed consent was given by all patients according to the Declaration of Helsinki and the Austrian Law on Gene Technology.
Biochemical assays
Fasting citrated blood was collected, immediately placed on ice and centrifuged within 60 minutes at 2000 g at 4°C (20 min). Plasma aliquots were snap frozen and stored at Ϫ70°C. Citrated blood was kept at Ϫ20°for isolation of DNA. All laboratory investigations were performed at the Department of Laboratory Medicine at the University of Vienna.
Total (that is, free plus protein-bound) plasma homocysteine concentrations were determined by automated high-performance liquid chromatography (HPLC) with reverse-phase separation and fluorescent detection using a commercially available kit (Immundiagnostik, Bensheim, Germany) according to the method originally described by Araki and Sako [17] . Hyperhomocysteinemia was defined as total homocysteine levels above 15 mol/liter.
Plasma folate (5-methyltetrahydrofolate) and vitamin B 12 levels were measured with a radioassay which allowed simultaneous determination of both vitamin concentrations in a single reaction tube (SimulTRAC-SNB, Becton Dickinson, Ontario, Canada). Folate deficiency was considered present at a plasma concentration of less than 3.4 nmol/liter. Vitamin B 12 deficiency was defined as a concentration of less than 118 pmol/liter, respectively.
Polymerase chain reaction analysis of MTHFR gene
Identification of the 677 C to T transition in the MTHFR gene was performed as previously described [6] . In brief, 500 l of citrated blood was frozen twice (Ϫ70°C). Cellular DNA was obtained by thawing and boiling for 10 minutes, followed by centrifugation at 12,000 g (10 min). The supernatants were collected and 5 l of a 1:10 dilution were used in a 50 l polymerase chain reaction (PCR) reaction containing 10 mM Tris-HCl (pH 8.8), 50 mM KCl, 0.1% Triton X-100, 1.25 mM MgCl 2 , 0.2 mM of each nucleoside triphosphate, 30 pmol of each primer and 1.25 units of AmpliTaq DNA Polymerase (Perkin Elmer Cetus, Norwalk, CT, USA). PCR was performed using the primers described by Frosst and colleagues: 5Ј-TGAAG-GAGAAGGTGTCTGCGGGA-3Ј and 5Ј-AGGACGGTGCG-GTGAGAGTG-3Ј [6] . Thermocycling conditions consisted of 40 cycles of denaturation at 95°C for one minute, annealing at 60°C for one minute and extension at 72°C for one minute, preceded by an initial denaturation step at 95°C for three minutes and followed by a terminal extension of five minutes at 72°C. Two microliters of the 198-bp PCR product were subjected to HinfI digestion (0.5 Units enzyme in a 20 l digest). The presence of a mutation creates a HinfI recognition sequence that leads to digestion of the 198 bp PCR product into fragments of 175 bp and 23 bp, respectively. Heterozygous subjects show three fragments (198 bp, 175 bp and 23 bp), whereas a homozygous C to T transition results in the production of two fragments of 175 bp and 23 bp. HinfI digests of PCR amplification products were analyzed by electrophoresis through 6% polyacrylamide gels (Novex, San Diego, CA, USA) followed by ethidium bromide staining.
Statistical methods
Comparison of the frequency of the different MTHFR alleles in peritoneal dialysis patients and the control group was performed by chi square test. Since plasma total homocysteine and folate measures were positively skewed, natural logarithmic transformation was used to normalize the distribution (natural logarithm of total homocysteine/folate concentrations, ln-total homocysteine/ ln-folate). Descriptive statistics included mean values Ϯ SD, geometric means, medians, full ranges and 10th to 90th percentile ranges for total homocysteine plasma levels, vitamin B 12 and folate levels.
Separate comparisons of the total homocysteine plasma levels 
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between (C/C), (C/T) or (T/T) subjects were performed by analysis of covariance. The covariables were folate, vitamin B 12 , age, gender, albumin, serum creatinine, weekly Kt/V, weekly creatinine clearance, residual renal function, dialysis center, mode of peritoneal dialysis (CAPD or APD) and vitamin intake in peritoneal dialysis patients. Individual comparisons between the groups were conducted by post hoc analysis (Scheffe's test).
For both the patient and the control group (factor: group) an analysis of covariance with the factors MTHFR [dummy variables: (C/C) versus (T/T) and (C/T) versus (T/T)] and group, the covariables age, gender, folate and B 12 level, which were available for both groups (patients and controls), and the calculations for interaction terms group ϫ MTHFR, group ϫ age, group ϫ gender, group ϫ plasma folate levels and group ϫ B 12 levels on the total homocysteine plasma levels were performed.
A similar model was applied for the analysis of influence of MTHFR (dummy variables, see above) and group as factors, and the covariables age and gender and the interaction terms group ϫ MTHFR, group ϫ age, group ϫ gender on plasma folate levels.
Unpaired comparisons of patient characteristics in subjects with and without cardiovascular disease and comparison of VDS 1 and VDS 2 in patients with total homocysteine levels above versus below the sample median or above versus below the cut off value of the normal range (Յ 15.0 mol/liter) were performed by Student's t-test (two tailed). All calculations were performed by the statistical software package SAS (SAS Institute Inc., Cary, NC, USA).
RESULTS
MTHFR gene polymorphism
In peritoneal dialysis patients the allelic frequency of the 677 C to T transition in the MTHFR gene was 0.29 and in age-and sex-matched healthy controls it was 0.34. Twelve of 154 patients (7.8%) showed a homozygous C677T mutation (T/T), 65 patients (42.2%) were heterozygous (C/T) and 77 patients (50.0%) did not carry this mutation (C/C). In the control group 21 of 154 healthy individuals (13.6%) were homozygous for the T allele, 64 (41.6%) were (C/T) and in 69 control subjects (44.8%) the mutation was not present. Comparison of the frequencies of the different MTHFR alleles in healthy subjects and peritoneal dialysis patients revealed no significant difference. The allelic frequency in the group of diabetic patients (0.29; N ϭ 47; Table 2 ) was similar to the allelic frequency in non-diabetic patients.
Total homocysteine plasma levels
Total homocysteine plasma levels were transformed to natural logarithmic data to normalize the distribution. The mean total homocysteine level in peritoneal dialysis patients was 25.6 Ϯ 19.8 mol/liter versus 9.7 Ϯ 3.3 mol/liter in control subjects.
Forty-six of 154 peritoneal dialysis patients (29.9%) had total homocysteine levels Յ 15.0 mol/liter, in contrast to 145 of 154 healthy subjects (94.2%). Of these 46 patients [23 patients were (C/T) and 22 patients (C/C), respectively], only one was homozygous for the MTHFR gene variation, whereas in the control group 19 of 145 subjects with total homocysteine levels Յ 15.0 mol/liter were identified as homozygotes for the MTHFR mutation. The geometric mean total homocysteine levels in (T/T) patients were more than two times higher than total homocysteine levels of (C/T) patients and patients without the mutation (Table 3) .
There was a significant influence of the MTHFR gene-polymorphism (P ϭ 0.0001), vitamin B 12 (P ϭ 0.0001), folate (P ϭ 0.0005), creatinine (P ϭ 0.016), serum albumin levels (P ϭ 0.0157) and dialysis center (P ϭ 0.0173) on ln-total homocysteine plasma levels in peritoneal dialysis patients. The mean total homocysteine level was 61.7 Ϯ 40.1 mol/liter in (T/T) peritoneal dialysis patients [P Ͻ 0.05 vs. (C/T) and (C/C) patients] and 10.4 Ϯ 5.7 mol/liter in (T/T) controls. In (C/T) patients the mean total homocysteine concentration was 23.1 Ϯ 15.8 mol/liter versus 9.8 Ϯ 2.9 mol/liter in (C/T) controls. In (C/C) peritoneal dialysis patients the mean total homocysteine level was 22.2 Ϯ 11.1 mol/liter versus 9.4 Ϯ 2.5 mol/liter in (C/C) controls (Fig. 1) . The (T/T) allele resulted in an estimated increase in total homocysteine levels of 127% (more than doubling) compared to the (C/T) and as much as 150% compared to the (C/C) patients. An increase of the vitamin B 12 level of 100 pmol/liter resulted in an estimated decrease of total homocysteine levels of 8.9%, and an increase of folate levels of 10 nmol/liter resulted in a decrease of 4%. In contrast, an increase of serum albumin level of 1 g/liter resulted in an estimated increase of 2% and an increase of creatinine of 1 mg/dl resulted in an estimated increase of total homocysteine levels of 7%. The significant center effect in our analysis was due to relative many (T/T) patients with high total homocysteine plasma levels in one small center. The other covariables (weekly Kt/V, residual renal clearance, weekly creatinine clearance, age, gender, duration of dialysis, and vitamin intake) showed no significant influence on total homocysteine levels.
For the overall analysis of ln-total homocysteine levels of patients and controls, there was a significant influence of the factor group (P ϭ 0.0001), of the covariables age (P ϭ 0.0006) and gender (P ϭ 0.0003), and significant interaction terms group ϫ MTHFR [for (C/C) versus (T/T), P ϭ 0.0001, for (C/T) versus (T/T), P ϭ 0.0001], group ϫ age (P ϭ 0.0002), and group ϫ B 12 level (P ϭ 0.0002). The total homocysteine levels were more than twofold higher in the patient group than in the control group. Furthermore, total homocysteine levels significantly varied among the MTHFR groups of the patient group and the control group. The most striking finding was that patients homozygous for the T allele had particularly high total homocysteine values ( Table 3) . The total homocysteine levels in the control group were increasing in older control people, whereas in the patient group the total homocysteine levels were nearly constant with advancing age. In the control group there was no influence of vitamin B 12 levels on There were no significant differences in the frequencies of different MTHFR genotypes or allelic frequencies between peritoneal dialysis patients, the subgroup of diabetic patients and control subjects.
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total homocysteine levels, while in the patient group a negative correlation was observed. Folate levels had no influence on total homocysteine concentrations in this analysis including both patients and controls.
Vitamin concentrations
The mean folate concentration was 22.9 Ϯ 36. Table 3 .
Cardiovascular disease and relation to total homocysteine levels
Sixty-seven of 154 patients had evidence of vascular disease (43.5%). In patients with cardiovascular disorders, the geometric mean total homocysteine level was 18.5 mol/liter versus 22.8 mol/liter in those without vascular disease (NS). The only significant differences between these two patient groups were the patients' gender and age, creatinine and serum albumin levels and the number of diabetic patients (Table 4) . Vascular disease scores were analyzed in all patients with cardiovascular disease and in vascular disease patients with and without diabetes mellitus. The mean VDS 1 and mean VDS 2 in patients with cardiovascular disease and in patients with and without diabetes mellitus with respect to total homocysteine concentrations are summarized in Table 5 . Diabetic patients with total homocysteine levels above the sample median had a higher mean VDS 1 and VDS 2 compared to patients with total homocysteine levels below the sample median (Table 5) .
DISCUSSION
The present study demonstrates that peritoneal dialysis patients who are homozygous for the C677T polymorphism in the 
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MTHFR gene have significantly higher total homocysteine plasma levels (61.7 Ϯ 40.1 mol/liter) than heterozygous patients (23.1 Ϯ 15.8 mol/liter) or non-carriers (22.2 Ϯ 11.1 mol/liter). Vitamin B 12 , folate, creatinine, albumin concentrations and dialysis center, but not age, gender, weekly Kt/V, weekly creatinine clearance, residual renal function, duration and mode of peritoneal dialysis and the vitamin intake had a significant influence on plasma total homocysteine concentrations. The MTHFR polymorphism also significantly influenced plasma folate levels of peritoneal dialysis patients and healthy subjects. In diabetic patients with vascular disease the vascular disease morbidity was more pronounced if total homocysteine plasma levels above the sample median were present. The allelic frequency of the (C677T) transition in the MTHFR gene was not different between healthy subjects, all peritoneal dialysis patients and the subgroup of diabetic patients. Elevated homocysteine levels were initially suspected in endstage renal disease patients in 1972 by Robins and colleagues [18] and were later confirmed by others [19 -22] . Subsequently, hyperhomocysteinemia has been shown to be associated with an increased frequency of atherosclerotic vascular disease and was established as an independent risk factor for cardiovascular complications in chronic renal failure patients [1] [2] [3] [4] [5] 23] .
In the first study conducted in a small population of CAPD patients, Hultberg, Andersson and Sterner [11] compared total homocysteine levels in three different patient groups receiving folate and vitamin B 6 substitution therapy. The median total homocysteine plasma level was 24.0 mol/liter in 17 CAPD patients, 27.9 mol/liter in 29 hemodialysis patients, and 23.5 mol/liter in 30 chronic renal failure patients. In this report, the authors also studied the diurnal variations of total homocysteine levels in a subset of these patients and did not find a significant increase of total homocysteine levels following a meat-rich meal. Also, in another recent study by Janssen and associates no daytime variations of total homocysteine plasma concentrations in CAPD patients have been observed [13] .
It is well established that folate supplementation therapy has a lowering effect on homocysteine concentrations [24, 25] . Total homocysteine plasma levels decreased from 50.2 Ϯ 5.6 mol/liter to 16.6 Ϯ 1.9 mol/liter during six weeks of folate therapy (5 mg/day) in 10 CAPD patients compared to a decrease of 55.7 Ϯ 10.1 mol/liter to 24.0 Ϯ 2.0 mol/liter in 10 hemodialysis patients [12] . After 12 and 26 weeks following cessation of folate substitution, total homocysteine levels gradually increased again but did not reach the pretreatment values [12] . Kim and coworkers [14] compared total homocysteine plasma levels in 12 CAPD patients, 5 hemodialysis patients and 10 healthy controls who did not receive vitamin substitution therapy. Total homocysteine plasma levels in these patients were 32.7 Ϯ 18.5 mol/liter, 25.2 Ϯ 10.9 mol/liter, and 14.0 Ϯ 4.0 mol/liter, respectively. The authors did not find a correlation with age, vitamin B 6 levels, residual renal function, protein catabolic rate or Kt/V. However, a significant correlation with an arbitrary atherosclerosis score was observed.
Robinson and collaborators [3] investigated the risk of development of cardiovascular disease in 176 end-stage renal failure patients with hyperhomocysteinemia. They found an independent odds ratio of 2.9 (confidence interval 1.4 to 5.8, P Ͻ 0.007) for vascular complications in patients with a total homocysteine concentration in the upper two quintiles (Ͼ 27.8 mol/liter). Hemodialysis patients (N ϭ 130) in this study showed higher total homocysteine levels (29.5 Ϯ 1.7 mol/liter) than peritoneal dialysis patients (N ϭ 46; 19.5 Ϯ 1.7 mol/liter, P Ͻ 0.01). Ninety-five percent of patients with vascular disease and 54% of patients without vascular disease were on hemodialysis treatment [3] .
The pathogenesis leading to elevated homocysteine concentrations in renal failure patients is only partially understood. The kidney itself is supposed to play a substantial role in homocysteine metabolism, and hyperhomocysteinemia has been shown to progress in parallel with the decline of renal function [5, 11, 26 -29] despite the negligible urinary excretion of homocysteine [30] . Bostom and colleagues demonstrated that the total homocysteine content in renal vein blood of rats is much lower compared to the total homocysteine concentration in the renal artery [30] . Based on this observation it was speculated that homocysteine might not reach the renal metabolic site in case of a decreased glomerular filtration rate. Furthermore, uremic toxins are supposed to contribute to hyperhomocysteinemia by inhibition of enzymes required for homocysteine metabolism. Perna and colleagues demonstrated that hyperhomocysteinemia can lead to intracellular accumulation of S-adenosyl-homocysteine, resulting in an impairment of remethylation pathways in uremia [31] [32] [33] .
Besides age, gender and nutritional factors including vitamin status and albumin concentration [3, 4] , a genetic defect in the MTHFR gene (C677T transition) was recently shown to result in elevated total homocysteine concentrations in homozygous hemodialysis patients [10] . The enzyme MTHFR represents an important cofactor involved in the homocysteine remethylation pathway. Decreased MTHFR activity results in inadequate production tHcy is total homocysteine. a P Ͻ 0.05
of 5-methyltetrahydrofolate, which is required for the remethylation of homocysteine to methionine, with the consequence of elevated plasma total homocysteine concentrations [34, 35] . The frequency of the different MTHFR alleles in our patients was comparable to the frequency observed in age-and gendermatched healthy individuals. Recently, the influence of the MTHFR polymorphism on total homocysteine plasma levels in subjects with normal renal function was shown to be limited to those having suboptimal folate levels [9] . Even though the homozygous (T/T) MTHFR polymorphism may lead to elevated total homocysteine levels in healthy subjects, the increase was not significant in this study.
In contrast, total homocysteine levels in (T/T) homozygous peritoneal dialysis patients were significantly higher (more than twofold) compared to (C/T) and (C/C) patients. This increase is much higher compared to the levels in hemodialysis patients [43% increase of total homocysteine levels in (T/T) versus (C/C) patients] [10] . This striking difference in total homocysteine concentrations of (T/T) hemodialysis and (T/T) peritoneal dialysis patients might be associated with, at least in part, the lower, but still normal folate and vitamin B 12 levels observed in the group of (T/T) peritoneal dialysis patients.
In several studies hemodialysis patients had higher total homocysteine concentrations compared to peritoneal dialysis patients [3, 11, 14] . These data are in line with our own observation on hemodialysis patients showing a mean total homocysteine level of 28.7 Ϯ 11 mol/liter [10] compared to the mean total homocysteine level of 25.6 Ϯ 19.8 mol/liter for peritoneal dialysis patients of this study. Peritoneal dialysis patients presented with lower mean folate but higher mean vitamin B 12 plasma levels compared to the hemodialysis patients from our previous study (folate levels, 22.9 nmol/liter vs. 26.6 nmol/liter; vitamin B 12 levels, 336.1 pmol/liter vs. 276.9 pmol/liter, respectively). Therefore, separate analyses of the total homocysteine levels, of the influence of the (C677T) MTHFR polymorphism, and of cofactors involved in homocysteine metabolism, have to be performed in patients with different modes of renal replacement therapy. Furthermore, a separate investigation of cardiovascular risk factors, morbidity and mortality in hemodialysis and peritoneal dialysis patients appears to be mandatory for future studies.
There was a significant influence of vitamin B 12 , folate, creatinine, and albumin levels on total homocysteine plasma concentrations of peritoneal dialysis patients in the present study, which is in line with previous observations in renal failure patients [3, 4] . It can be speculated that total homocysteine concentrations may reflect the nutritional status because we observed a significant influence of albumin concentrations in our analyses. However, the distribution of patients with moderate hyperhomocysteinemia (30 to 100 mol/liter) was comparable in patients with albumin levels between 30 and 40 g/liter and between 40 and 50 g/liter with respect to the different MTHFR alleles (Fig. 2) . Low dose vitamin supplementation in some of the patients had no influence on total homocysteine concentrations in our study.
High dose folate therapy has been demonstrated to lower total homocysteine plasma concentrations in end-stage renal failure patients despite the commonly observed high folate levels of these patients, which is probably linked to intracellular folate deficiency [13, 16, 25] . A potential effect of low intracellular folate concentrations on total homocysteine plasma levels in our peritoneal dialysis patients cannot be ruled out. Nevertheless, there was a significant influence of folate plasma levels on total homocysteine concentrations in our analyses. The homozygous C677T MTHFR transition was recently shown to affect red cell folate and plasma folate concentrations in pregnant women and red cell folate levels in nonpregnant women [37] . Our study also demonstrates that the MTHFR polymorphism significantly influences plasma folate levels in peritoneal dialysis patients and healthy subjects [the median folate concentration was lower in (TT) subjects compared with (CT) and (CC) subjects; Table 3 ]. Thus, low 5-methyltetrahydrofolate levels in individuals with the (T/T) MTHFR allele do not necessarily reflect a suboptimal folate intake, but may point to decreased formation of active folate resulting from the presence of a thermolabile MTHFR variant. This status leads to elevated total homocysteine levels due to decreased conversion of homocysteine to methionin, which might be overcome by increased folate intake [24, 25] .
It can be hypothesized that the extent of hyperhomocysteinemia in dialysis patients might be influenced by geographical factors. Recently, a European-wide survey on total homocysteine levels in subjects without renal failure revealed significant variations in total homocysteine plasma levels in different cities and countries [36] . In this study genetic and nutritional influences on total homocysteine levels were not considered [36] . In the present study a center effect on total homocysteine levels was observed, which was due to the relatively greater proportion of (T/T) patients with high total homocysteine levels in a center with few patients. In healthy subjects age and sex influence total homocysteine plasma concentrations, whereas in patients with renal failure the MTHFR polymorphism, folate and vitamin B 12 concentrations are much more important. Abbreviations are: VDS 1, vascular disease score 1; VDS 2, vascular disease score 2; tHcy, total homocysteine. The median total homocysteine level was 18.4 mol/liter for all patients with vascular disease, 18.4 mol/liter for diabetic patients with vascular disease and 17.9 mol/liter for non-diabetic patients with vascular disease.
a P ϭ 0.0211 vs. VDS 1, and b P ϭ 0.020 vs. VDS 2 in diabetic patients with vascular disease and total homocysteine levels Յ sample median.
In hemodialysis patients, plasma total homocysteine concentrations can be transiently lowered by dialysis treatment [11, 18] . In the present study, however, no significant influence of duration and mode of peritoneal dialysis treatment, weekly Kt/V, residual renal function and weekly creatinine clearance on total homocysteine levels was observed in peritoneal dialysis patients. These findings extend the results obtained in previous studies describing no influence of Kt/V on total homocysteine levels in a small patient population [14] .
The cardiovascular morbidity and mortality of dialysis patients is increased manyfold compared to healthy subjects [37] [38] [39] . This finding was suggested to be associated with elevated total homocysteine plasma levels [1] [2] [3] [4] , although no separate analysis in hemodialysis and peritoneal dialysis patients was conducted in these studies. It was not the goal of the present study to demonstrate that total homocysteine levels represent an independent risk factor for cardiovascular disease. Therefore, lipid profiles, Lp(a), fibrinogen levels and other known cardiovascular risk factors were not considered in our analyses. Interestingly, a high proportion of our patients presented with total homocysteine concentrations within the normal range and comparison of patients with and without evidence of cardiovascular disease revealed no significant difference of total homocysteine levels in either patient groups. It has to be mentioned, however, that there were significantly more diabetic patients in the group with vascular disease. Furthermore, the mean age in patients with vascular disease was significantly higher and the mean albumin level was significantly lower in these patients. Interestingly, serum creatinine levels in patients with vascular disease were lower compared to those without vascular disease. Nevertheless, we found a significant increase of vascular morbidity in diabetic patients with total homocysteine levels above the sample median. This finding points to the multifactorial genesis of atherosclerosis in end-stage renal failure patients.
In conclusion, the present study provides evidence that homozygosity for the C677T polymorphism in the MTHFR gene as well as low vitamin B 12 and low folate levels result in aggravation of hyperhomocysteinemia in peritoneal dialysis patients. Furthermore, the MTHFR polymorphism influences folate levels in both the patient group and in healthy individuals. Elevated total homocysteine levels in our diabetic peritoneal dialysis patients with vascular disease are associated with increased cardiovascular morbidity. Vitamin therapy in end-stage renal failure patients is strongly encouraged, especially if further studies prove a beneficial effect of folate or vitamin B 12 intervention on vascular disease morbidity and mortality in these patients.
